Skip to content
Review

Abstract 11954: Left Atrial Appendage Closure versus Direct Oral Anticoagulants in Non-Valvular Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Direct oral anticoagulants (DOACs) are the standard strategy for stroke prevention in non-valvular atrial fibrillation (AF), but long-term anticoagulation may be unsuitable for some patients because of bleeding risk or intolerance. Left atrial appendage closure (LAAC) has emerged as an alternative approach; however, comparative data between LAAC and DOACs remain limited. We performed an updated systematic review and meta-analysis incorporating recently reported randomized trial data to compare clinical outcomes between LAAC and DOAC therapy. Methods: PubMed, Embase, Cochrane Library, and major cardiovascular meeting databases were systematically searched for studies comparing LAAC with DOACs in patients with non-valvular AF. Randomized and observational studies reporting clinical outcomes of interest were included. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Primary outcomes included all-cause mortality, major adverse cardiovascular events (MACE), clinically relevant bleeding, stroke/transient ischemic attack (TIA), systemic embolism, and cardiovascular death. Results: Nineteen studies, including five randomized trials and fourteen observational cohorts, comprising more than 25,000 patient-years of follow-up were analyzed. Compared with DOAC therapy, LAAC was associated with lower all-cause mortality (RR 0.67, 95% CI 0.56-0.79; p<0.0001), reduced MACE (RR 0.73, 95% CI 0.57-0.94; p=0.01), and lower clinically relevant bleeding (RR 0.74, 95% CI 0.65-0.83; p<0.0001). Rates of stroke/TIA (RR 0.96, 95% CI 0.83-1.12; p=0.63), systemic embolism (RR 0.95, 95% CI 0.77-1.17; p=0.62), and cardiovascular death (RR 0.90, 95% CI 0.69-1.17; p=0.43) were similar between groups. In randomized-trial-only analyses, reductions in mortality and bleeding were attenuated and no longer statistically significant. Conclusions: Among patients with non-valvular AF, LAAC was associated with lower all-cause mortality, MACE, and clinically relevant bleeding compared with DOAC therapy, while maintaining similar protection against stroke, systemic embolism, and cardiovascular death. The attenuation of benefit in randomized-trial analyses suggests that residual confounding may contribute to observed differences and highlights the need for additional adequately powered randomized studies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.